Last reviewed · How we verify
Erbitux,merck serono — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Erbitux,merck serono (Erbitux,merck serono) — Rabin Medical Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Erbitux,merck serono TARGET | Erbitux,merck serono | Rabin Medical Center | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Erbitux,merck serono CI watch — RSS
- Erbitux,merck serono CI watch — Atom
- Erbitux,merck serono CI watch — JSON
- Erbitux,merck serono alone — RSS
Cite this brief
Drug Landscape (2026). Erbitux,merck serono — Competitive Intelligence Brief. https://druglandscape.com/ci/erbitux-merck-serono. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing